Gapping down
In reaction to disappointing earnings/guidance:
- PDD -21.9%, URBN -15.4%, PAGS -4.8%, ALC -2.2%, CRM -1% (guidance)
Other news:
- IDYA -10.4% (presents data from ongoing Phase 1/2 clinical trial evaluating the tolerability and preliminary clinical activity of IDE196)
- ORGO -5.9% (to sell 9 mln shares of its Class A common stock in an underwritten public offering)
- CRSP -4.7% (announces public offering of 4.25 mln common shares)
- MGP -3.4% (prices upsized underwritten public offering of 30 mln Class A shares at a public offering price of $31.25 per share)
- MTZ -2.8% (attributed to block trade pricing)
- NYMT -2.7% (prices offering of 25 mln shares of common stock at for gross proceeds of $152.5 mln)
- AEO -2.4% (following URBN results)
- MSEX -2.2% (prices offering of 661,157 shares of its common stock at a price to the public of $60.50 per share)
- BABA -1.4% (prices global offering of 500 mln ordinary shares at approximately $180 per ADS)
Analyst comments:
- AMRN -6.5% (initiated with Underperform at Oppenheimer; tgt $7)
- RIG -2.4% (initiated with a Sell at Deutsche Bank)
- CBOE -1.3% (downgraded to Neutral from Buy at Goldman and removed from Conviction Buy List)
- ASH -1.3% (downgraded to Market Perform from Outperform at BMO Capital Markets)
- KSS -0.9% (downgraded to Neutral from Buy at Goldman)